Sugandha Dureja
Sugandha Dureja publishes mostly in Epidemiology, Oncology and Neurology, on topics such as Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies and Neuroblastoma Research and Treatments.
- World rank
- #5,182,834 of 7,710,434 ranked researchers
- Rank in India
- #145,392 of 280,097
- Works
- 28
- Citations
- 195
- Citations per work
- 7.0
What does Sugandha Dureja research?
Sugandha Dureja's work is mostly in Medicine (87%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2487.2%
- Medicine2487.2%
- Everything else412.8%
- 1Epidemiology27% of their works
- 2Oncology24% of their works
- 3Neurology14% of their works
- 4Radiology, Nuclear Medicine and Imaging12% of their works
- 5Pulmonary and Respiratory Medicine8% of their works
- 6Public Health, Environmental and Occupational Health3% of their works
Research topics
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Gestational Trophoblastic Disease Studies
- Prostate Cancer Treatment and Research
Which keywords describe Sugandha Dureja's research?
The keywords of their largest research topics: Genetic Mutations, Immunotherapy, Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Targeted Therapy, Chemotherapy, Biomarkers and Prognostic Factors.
- Sunitinib
- Pancreatic Cancer
- Hydatidiform Mole
- Androgen Receptor
- Radioimmunotherapy
- Neuroblastoma
- Small-Cell Lung Cancer
- Prognostic Factors
- Chemotherapy
- Pancreatic Neuroendocrine Tumors
- Immunotherapy
- Genetic Mutations
- Neuroendocrine Tumors
- Targeted Therapy
- Biomarkers
- Genomic Profiles
- ALK
- PET Imaging
- Radiopharmaceuticals
- Gestational Trophoblastic Disease
- Imatinib Mesylate
- Prostate Cancer
- Surgical Complications
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Genetic Mutations343 topics
- Immunotherapy314 topics
- Neuroendocrine Tumors211 topic
- Pancreatic Neuroendocrine Tumors211 topic
- Targeted Therapy212 topics
- Chemotherapy203 topics
- Biomarkers182 topics
- Prognostic Factors182 topics
- Genomic Profiles161 topic
- Small-Cell Lung Cancer161 topic
- ALK111 topic
- Neuroblastoma111 topic
- PET Imaging72 topics
- Radioimmunotherapy51 topic
- Radiopharmaceuticals51 topic
- Androgen Receptor21 topic
- Gestational Trophoblastic Disease21 topic
- Hydatidiform Mole21 topic
- Imatinib Mesylate21 topic
- Pancreatic Cancer21 topic
- Prostate Cancer21 topic
- Sunitinib21 topic
- Surgical Complications21 topic
Where does Sugandha Dureja work?
Sugandha Dureja's main affiliation in the publication record is Fortis Memorial Research Institute, India.
How many publications and citations does Sugandha Dureja have?
OpenAlex counts 28 works and 195 citations for Sugandha Dureja, an h-index of 6, ranking #5,182,834 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Sugandha Dureja. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.